- Home
- ZGN vs ADPT Comparison
ZGN vs ADPT Comparison
Compare ZGN & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZGN
- ADPT
- Stock Information
- Founded
- ZGN 1910
- ADPT 2009
- Country
- ZGN Italy
- ADPT United States
- Employees
- ZGN N/A
- ADPT N/A
- Industry
- ZGN Apparel
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZGN Consumer Discretionary
- ADPT Health Care
- Exchange
- ZGN Nasdaq
- ADPT Nasdaq
- Market Cap
- ZGN 2.7B
- ADPT 2.6B
- IPO Year
- ZGN N/A
- ADPT 2019
- Fundamental
- Price
- ZGN $10.73
- ADPT $19.62
- Analyst Decision
- ZGN Buy
- ADPT Strong Buy
- Analyst Count
- ZGN 5
- ADPT 10
- Target Price
- ZGN $10.22
- ADPT $16.60
- AVG Volume (30 Days)
- ZGN 496.6K
- ADPT 2.5M
- Earning Date
- ZGN 09-05-2025
- ADPT 11-05-2025
- Dividend Yield
- ZGN 1.30%
- ADPT N/A
- EPS Growth
- ZGN N/A
- ADPT N/A
- EPS
- ZGN 0.43
- ADPT N/A
- Revenue
- ZGN $2,248,050,499.00
- ADPT $252,754,000.00
- Revenue This Year
- ZGN N/A
- ADPT $36.43
- Revenue Next Year
- ZGN $4.55
- ADPT $12.31
- P/E Ratio
- ZGN $24.68
- ADPT N/A
- Revenue Growth
- ZGN N/A
- ADPT 42.57
- 52 Week Low
- ZGN $6.05
- ADPT $5.29
- 52 Week High
- ZGN $10.80
- ADPT $20.76
- Technical
- Relative Strength Index (RSI)
- ZGN 62.87
- ADPT 67.55
- Support Level
- ZGN $9.58
- ADPT $13.28
- Resistance Level
- ZGN $9.98
- ADPT $20.76
- Average True Range (ATR)
- ZGN 0.31
- ADPT 1.12
- MACD
- ZGN 0.06
- ADPT 0.58
- Stochastic Oscillator
- ZGN 93.83
- ADPT 84.89
About ZGN Ermenegildo Zegna N.V.
Ermenegildo Zegna NV designs creates, and distributes luxury menswear and accessories under the Zegna brand, as well as womenswear, menswear, and accessories under the Thom Browne brand. The company operates in three segments: the Zegna segment (comprising three product lines: Zegna Branded Products, Textile, and Third Party Brands); the Thom Browne segment, and the Tom Ford Fashion segment. The company generates the majority of its revenue from the Zegna segment.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).